MEF2C

Across TCGA pan-cancer cohorts, MEF2C mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MEF2C’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where MEF2C mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MEF2C is over-expressed in tumor, although a few such as LSCC and PDAC show the opposite, repressed pattern.

LSCC, CCRCC, and PDAC are the cancer types where MEF2C tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MEF2C mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	III,IV	−0.695	<.001	7	view →
CCRCC	Male	All	+0.661	<.001	6	view →
PDAC	Male	III,IV	−0.710	.039	1	view →
LUAD	Female	III,IV	−0.180	.005	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MEF2C–LSCC

Open the LSCC breakdown →